// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1151 Abstracts

Case report: A hepatoerythropoietic porphyria treated with hydroxychloroquine

Desiree Lee - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

Hydroxychloroquine

Association of porphyria cutanea tarda and lupus erythematosus and its importance for clinical management.

Samia Arbache - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Adult-onset Still’s disease with prurigo pigmentosa-like persistent papules and plaques

Yi-Chin Chen - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Dermatology

N/A

Hydroxychloroquine

Anatomical colocalization of vitiligo and cutaneous lupus

Cristina Vzquez-Rodrguez - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Treatment of Discoid Lupus Erythematosus with Pulsed Dye Laser

Kelsey Flood - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Treatment of hydroxychloroquine-induced hyperpigmentation of the lower extremities with the Q-switched 755-nm alexandrite laser

Elizabeth Damstetter - American Academy of Dermatology (AAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

“AIMING FOR THE BULLSEYE”: RETINAL TOXICITY SCREENING FOR HYDROXYCHLOROQUINE THERAPY – ARE WE HITTING THE TARGET?

S. Gubbins - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

EFFECT OF TOCILIZUMAB IN DMARD-NAÏVE EARLY RHEUMATOID ARTHRITIS PATIENTS ON HEALTH-RELATED QUALITY OF LIFE: RESULTS OF THE U-ACT-EARLY TRIAL

X.M. Teitsma - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

EFFICACY AND SAFETY OF YISAIPU, A RECOMBINANT HUMAN TUMOR NECROSIS FACTOR-α RECEPTOR II IGG FC FUSION PROTEIN IN CHINESE PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS

R. Wu - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

HYDROXYCHLOROQUINE'S IMPACT IN RENAL BIOPSY AND OUTCOMES OF LUPUS NEPHRITIS

D. Navarro - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

NUCLEIC ACIDS OXIDATIVE STRESS STATUS IN SJÖGREN'S SYNDROME

D. Tecer - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

PREDICTORS OF PERSISTENT DISEASE ACTIVITY AND PERSISTENT LONG QUIESCENCE IN SYSTEMIC LUPUS ERYTHEMATOSUS – RESULTS FROM THE HOPKINS LUPUS COHORT

I. Giannakou - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

SYSTEMS BASED INVESTIGATION OF THE ANTI-IMMUNOGENIC POTENTIAL OF DMARDS FOR RHEUMATOID ARTHRITIS USING HUMAN PRIMARY CELL-BASED BIOMAP® PHENOTYPIC PROFILING

A. O'Mahony - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Hypoglycaemia due to hydroxychloroquine in a patient who underwent Roux-en-Y gastric bypass surgery

Kamrudeen Mohammed - European Congress of Endocrinology (ECE) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Hydroxychloroquine

Type B insulin resistance syndrome in a patient with connective tissue disease

Agnieszka Lebkowska - European Congress of Endocrinology (ECE) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Autophagic cell death with hydroxychloroquine in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.

Mridula Annette George - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Hydroxychloroquine

Safety and preliminary activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma (mRCC): A cytokine working group study.

Leonard Joseph Appleman - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Hydroxychloroquine

Sjogren's syndrome in a patient previously diagnosed as seasonal affective disorder

M.E.Ceylan - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Dental and Oral Health

N/A

Hydroxychloroquine

Phase I/II trial assessing hydroxychloroquine and itraconazole in women with advanced platinum-resistant epithelial ovarian cancer (EOC) (HYDRA-01).

Ainhoa Madariaga - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Hydroxychloroquine

The European Vasculitis Society 2016 Meeting Report

Ingeborg M. Bajema - International Society of Nephrology (ISN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

Hydroxychloroquine

Copyright © 2026. QuantiNova All rights reserved